Literature DB >> 17468914

Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data.

Zebadiah Kimmel1, Desiree Ratner, John Y S Kim, Jeffrey D Wayne, Alfred W Rademaker, Murad Alam.   

Abstract

BACKGROUND: The purpose of this study was to analyze available datasets to assess the degree of asymmetry typically associated with DFSP, and to study the optimal surgical approach for extirpating these tumors by clearing lateral margins.
METHODS: MEDLINE (1994-2004) was searched for English-language multi-patient series concerning DFSP. Case series were included if complete information could be obtained for: (a) two-dimensional preoperative tumor size as measured on the skin surface before removal; (b) postoperative tumor size, as estimated by the dimensions of the final wound defect. Four case series met these criteria, and the authors were contacted directly for unpublished raw data.
RESULTS: For each of 98 included tumors we computed: (1) the tumor index, a measure of clinically apparent tumor surface area; (2) clearance margin, or the theoretical best and worst-case surgical margins that would have been required for tumor clearance. We used this information to (a) assess the relationship between clinically apparent tumor size and final surgical margin; (b) determine the proportion of tumors of a given size that would be cleared by a margin of given width. We found that standard wide excision margin of 4 cm was predicted to provide a tumor clearance rate of 95% for tumors of preoperative size less than or equal to 3 cm x 3 cm.
CONCLUSIONS: There is a weak relationship between preoperative tumor size and the width of the final defect after clearance. Based on our calculations, very wide local excision is necessary for clearance of most DFSPs.

Entities:  

Mesh:

Year:  2007        PMID: 17468914     DOI: 10.1245/s10434-006-9233-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  A Rare Breast Tumor: Dermatofibrosarcoma Protuberans.

Authors:  Tevhide Bilgen Özcan; Ezgi Hacıhasanoğlu; Mehmet Ali Nazlı; Şefika Aksoy; Cem Leblebici; Canan Kelten Talu
Journal:  J Breast Health       Date:  2016-01-01

2.  Dermatofibrosarcoma Protuberans: A Rare Malignancy of the Breast.

Authors:  Salim Al-Rahbi; Taha Al-Lawati; Suad Al-Kharusi; Sosamma Thomas; Khoula Al-Harrasi
Journal:  Oman Med J       Date:  2015-09

3.  Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency.

Authors:  Chimene Kesserwan; Robert Sokolic; Edward W Cowen; Elizabeth Garabedian; Kerstin Heselmeyer-Haddad; Chyi-Chia Richard Lee; Stefania Pittaluga; Clarymar Ortiz; Kristin Baird; Dolores Lopez-Terrada; Julia Bridge; Alan S Wayne; Fabio Candotti
Journal:  J Allergy Clin Immunol       Date:  2011-12-06       Impact factor: 10.793

4.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Authors:  Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

5.  An unusual variant of atrophic dermatofibrosarcoma protuberans.

Authors:  Simone Silva da Costa Aragão; Everson José Dos Santos Leite; Alberto Eduardo Cox Cardoso; Ricardo Luiz Simões Houly
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896

6.  Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.

Authors:  Yan Fu; Huanrong Kang; Hui Zhao; Jia Hu; Huanhuan Zhang; Xiaosong Li; Nan Du; Yitao Huang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.

Authors:  Piotr Rutkowski; Agnieszka Wozniak; Tomasz Switaj
Journal:  Sarcoma       Date:  2011-03-30

8.  Recurrent Dermatofibrosarcoma Protuberance: A Case Report.

Authors:  Shiv Raj Shah; Sujan Regmee; Dhiresh Kumar Maharjan; Prabin Bikram Thapa
Journal:  JNMA J Nepal Med Assoc       Date:  2021-11-15       Impact factor: 0.556

9.  Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.

Authors:  Dennis A Wicherts; Frits van Coevorden; Houke M Klomp; Martine A van Huizum; J Martijn Kerst; Rick L M Haas; Hester H van Boven; J A van der Hage
Journal:  World J Surg Oncol       Date:  2013-03-08       Impact factor: 2.754

10.  Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.

Authors:  Jung Yong Hong; Xiao Liu; Mao Mao; Miao Li; Dong Il Choi; Shin Woo Kang; Jeeyun Lee; Yoon La Choi
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.